John Varian
CIK 1416176 · CEO · last filed 2026-01-09
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$821.3K
Companies
6
Total Filings
68
Lifetime Open-Market Net
-$2.49M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SLS | Director | 72,900 | $7.83 | $570.8K | $0 | 10 | 2026-01-09 |
| Acorda Therapeutics, Inc. (ACOR) Delisted | Director | — | $0.66 | — | $0 | 3 | 2023-06-23 |
| Zyla Life Sciences (EGLT) Delisted | Director | — | — | — | $0 | 1 | 2018-07-02 |
| Aravive, Inc. (VSAR) Delisted | Director | 22,280 | — | — | -$20.8K | 6 | 2017-12-22 |
| XOMA | CEO | 5,995 | $41.79 | $250.5K | -$2.47M | 41 | 2017-05-22 |
| ARYx Therapeutics, Inc. (ARYX) Delisted | COO & CFO | — | — | — | $0 | 3 | 2010-03-01 |
Recent Filings · Page 2 of 7
68 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2019-03-18 | SLS | Grant (A) | — | $0 | EDGAR |
| 2019-02-04 | — | Disp (D) | — | $0 | |
| 2018-07-02 | Zyla Life Sciences (EGLT) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-06-13 | SLS | Grant (A) | — | $0 | EDGAR |
| 2018-03-15 | SLS | Grant (A) | — | $0 | EDGAR |
| 2017-12-22 | Aravive, Inc. (VSAR) Delisted | Grant (A) | +11,200 | $0 | EDGAR |
| 2017-06-06 | Aravive, Inc. (VSAR) Delisted | Grant (A) | +3,480 | $0 | EDGAR |
| 2017-05-22 | XOMA | Grant (A) | — | $0 | EDGAR |
| 2017-05-18 | XOMA | Sell (S) | −39,540 | -$246.9K | EDGAR |
| 2016-12-23 | XOMA | Sell (S) | −13,549 | -$77.9K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.